Rosacea

NEW YORK — Signs of rosacea may be different in patients with darker skin types, but the symptoms remain the same, according to a presentation here.

NEW YORK — Clinical trials for rosacea lack diversity reflective of the U.S. census and disease rates, according to a poster presentation at the Skin of Color Update 2023 meeting.

Two phase 3 clinical trials evaluating DFD-29 for the treatment of adults with papulopustular rosacea achieved positive topline results, according to a Journey Medical Corporation press release.

Patients with rosacea, alopecia areata, psoriasis or atopic dermatitis all face an elevated risk for cardiovascular disease, according to a study.

The National Rosacea Society is launching a Seal of Acceptance program that will assist individuals suffering from rosacea in finding rosacea-friendly products, the society announced in a press release.

NEW YORK — A Tarsus executive said the company is looking forward to FDA approval of TP-03, a 0.25% lotilaner ophthalmic solution for treatment of Demodex blepharitis, in late summer 2023.

In honor of Rosacea Awareness Month, Healio has compiled a list of the most prevalent rosacea information published in 2023.

With April being Rosacea Awareness Month, the National Rosacea Society has brought to light the importance of consistency and patience when treating this chronic, inflammatory skin condition.

This year, Rosacea Awareness Month focuses on the importance of consistency and patience when trying new rosacea therapies, according to the National Rosacea Society.

Paroxetine was effective and well tolerated among patients with refractory erythema of rosacea with 42.9% of patients experiencing clear or almost clear results, according to a study.